Atherosclerosis and Cardiovascular Disease : 7th International Meeting
The advances in the field of atherosclerosis and cardiovascular disease continue at an increasingly rapid pace and it is an arduous task for those not directly involved to keep up with the latest developments. The papers presented at the 7th Meeting on Atherosclerosis and Cardiovascular Disease, held in Bologna, as part of the Ninth Centenary of the foundation of the University of Bologna, have been collected together here with the aim of providing all the latest information for doctors and research workers concerned with this important branch of medicine. We are pleased to be able to thank all those who joined us in celebrating the oldest university in the world. The scientific contributions, of the highest level, are valid proof of the tradition of exchanging experiences and of the continual up-dating of knowledge in the different sectors of lipid metabolism, genetics, physiopathology, pathological anatomy, bio- chemical and clinical diagnosis, diet, pharmacological and non-pharmacological ther- apy. The numerous contributions made by authors in the field of epidemiology and the prevention of atherosclerosis were also fundamental since not only research centres but also doctors all over the world are engaged in the battle which was defined by the WHO, twenty-five years ago, as the most important epidemic of the modern age.
- Hardback | 756 pages
- 01 Dec 1991
- Dordrecht, Netherlands
- 1990 ed.
- 756 p.
Table of contents
1 Cholesterol-CHD connection: evidence for the benefit of lipoprotein modification.- Epidemiological Studies on Atherosclerosis and Coronary Heart Disease.- 2 The effect of coronary heart disease prevention on the prevention of non-cardiovascular diseases.- 3 The meaning and relevance of intervention trials in prevention.- 4 Prospects for primary prevention of coronary heart disease.- 5 Dyslipemia in Portugal.- 6 The Brisighella study: plasma lipid trend in the elderly observed over a twelve year period.- Genetics of Coronary Heart Disease and Atherosclerosis: Clinical and Epidemiological Implications.- 7 FH gene phenotypic expression: insight for therapeutic strategy.- 8 Development of coronary heart disease in familial hypercholesterolemia.- 9 Effect of genes on levels and variability of risk factors for coronary heart disease.- 10 The type of mutation in apolipoprotein E determines whether type III hyperlipoproteinemia is expressed as a dominant or recessive trait.- The Vegetative Nervous System and Cardiovascular Disease.- 11 The sympatho-vagal balance and arterial hypertension.- 12 The autonomic disturbance accompanying myocardial infarction.- 13 The vegetative nervous system and atrial natriuretic factor.- Nosology of Hyperlipoproteinemias.- 14 Apolipoproteins and metabolism in atherosclerosis.- 15 Lipoprotein(a) and the LDL receptor (LDL-R): examination of the problem in a pedigree of rhesus monkeys with a familial hypercholesterolemia secondary to LDL-R deficiency.- 16 Clinical significance of apolipoprotein B containing lipoprotein particles.- 17 Hyperlipoproteinemia of lipoprotein Lp(a).- 18 LDL and atherosclerosis: from quantity to quality.- 19 Lipid distribution in human coronary lesions: analysis by digital imaging microscopy.- Nutrition: Population Studies.- 20 Time trends of risk factors for coronary heart disease in southern Italy.- 21 Nutritional aspects in the C.N.R. `D.I.S.CO.' Project.- 22 Nutrition habits in a free living community: the Brisighella study.- Nutrition: Special Diets and Metabolic Effects of Fats and Proteins.- 23 Experimental atherosclerosis: anomalous fats.- 24 Cholesterol-lowering action of diets rich in polyunsaturated fatty acids.- 25 Receptor-mediated catabolism of LDL in rabbits fed cholesterol-free, semipurified diets containing casein or soy protein: a time-course study.- 26 The effects of monounsaturated fatty acids on serum lipoprotien levels in healthy adult volunteers.- 27 Olive oil in nutrition and in prevention.- Athersclerosis, Computer Handling Studies and Mathematical Modelling.- 28 Some methods for medical image processing using supercomputers.- 29 A diffusion-governed model related to atheroma deposition.- 30 Mathematical model: interpolation and simulation.- 31 Limits of mathematical models in biology and medicine.- 32 The application of Markov process approach for the description of atherosclerotic phenomena.- 33 Utility and limits of a Markov birth process in the study and simulation of the atheroma evolution.- New Perspectives in the Treatment of Hypercholesterolemia and the Prevention of Atherosclerosis.- 34 Modification of lipoproteins in the intimai extracellular compartment that can contribute to atherogenesis.- LDL Apheresis: Efficacy Versus Ethical and Social Aspects.- 35 LDL apheresis: current situation in Japan.- 36 The effect of LDL-apheresis on some hemostatic parameters in homozygous familial hypercholesterolemia.- Developments in Lipoprotein and Apoprotein Research.- 37 Regulation of VLDL metabolism by cellular receptors.- 38 Current concepts in reverse cholesterol transport.- 39 Regulation of hepatic lipoprotein biosynthesis by hormones.- 40 Postprandial lipemia in patients with coronary artery disease.- 41 Lipid transport between plasma lipoproteins and cells: physicochemical regulation of lipid transfer rates and the secretion of very low density lipoproteins.- Thrombosis and Atherosclerosis: Clinical Insights.- 42 Hypercholesterolemia and haemostatic function changes.- 43 Predictive value of fibrinogen in arterial thrombosis.- Glycosaminoglycans and their Clinical Implications.- 44 Glycosaminoglycans and the proliferation of arterial smooth muscle cells.- Calcium Antagonists and Atherosclerosis.- 45 Do calcium antagonists inhibit atherogenesis?.- 46 Atherosclerosis-related effects of verapamil, anipamil and other calcium antagonists studied on cell culture.- 47 Antiatherosclerotic effects of anipamil, verapamil and other calcium antagonists studied on cell culture.- 48 Can the progression of coronary heart disease be influenced by calcium antagonists?.- Atherosclerosis Regression from a Clinical and Anatomo-Pathological Standpoint.- 49 A five year follow up of carotid atherosclerosis using B-mode imaging ultrasound.- 50 Preliminary results of the program on the surgical control of the hyperlipidemias (POSCH).- 51 The time course of atherosclerotic lesion regression in macaque monkeys.- 52 Human atherosclerosis and inflammation. An immunocytochemical and ultrastructural investigation.- 53 Carotid plaque volume measurement.- 54 Humoral factors of direct influence on the formation and regression of atheromatous plaques.- Atherosclerosis in Youth.- 55 The WHO-ISFC study on pathobiological determinants of atherosclerosis in youth (PBDAY): a first morphometric approach to aortic lesions.- 56 Atherosclerosis precursors in children. The Bologna study, an update.- 57 Lipid and apolipoprotein in cord blood.- New Lipid Lowering Agents.- 58 Probucol revisited.- 59 Controlled US studies of fenofibrate in the treatment of dyslipidemias.- 60 Effect of trapidil and its derivatives on the receptor-mediated low density lipoprotein metabolism by cultured human hepatic and extrahepatic cells.- 61 Bezafibrate: effects on serum lipoproteins and haemostatic factors.- LDL Apheresis.- 62 Efficiency and efficacy of LDL-apheresis performed at different intervals.- 63 Ischemic heart disease and plasmapheresis for cholesterol.- 64 Variables involved in the treatment of severe hyperlipoproteinemias by combined drug and LDL-apheresis treatment.- 65 Multiple effects of LDL-apheresis against progression of atherosclerosis in patients with familial hypercholesterolemia.- 66 Long-term LDL apheresis in FH.- 67 Long-term double filtration LDL-apheresis in familial hypercholesterolemia.- Standardization of Apoprotein Measurement in Blood.- 68 Apolipoprotein profile of a sample of Italian population. Correlations with coronary risk factors.- 69 A survey on apolipoprotein A-l and B: the CNR study.- 70 Reference standard for cholesterol evaluation in serum obtained by isotope dilution mass spectrometry.- Cardiologists and CHD and Atherosclerosis Prevention Versus Therapy.- 71 Incidence and prognostic significance of silent myocardial ischemia in patients after acute myocardial infarction.- 72 Chronic ischemic heart disease: prevention and therapy.- 73 Cholesterol and coronary heart disease - the pros and cons for action.- 74 Diagnosis and evaluation of ischemic heart disease.- 75 Antioxidant metabolic mechanisms in hypertensive and atherosclerotic arterial wall.- 76 Magnetic resonance of the heart.- 77 The role of HDL-subfractions in reverse cholesterol transport and its disturbances in tangier disease and HDL-deficiency with xanthomas.- Rationale for Prevention in High Risk Subjects.- 78 HDL cholesterol and triglycerides as risk factors for CHD.- 79 The ATS-Sardegna prevention campaign. Background and features.- 80 The Brisighella heart study report from 1984 to 1989.- Hyperlipoproteinemia Therapy: When to Opt for Drug Combinations.- 81 Drug combination therapy for selected hyperlipidemic patients.- 82 Hyperlipoproteinemia therapy: when to opt for drug combination?.- 83 Combined Pharmacological treatment of heterozygous familial hypercholesterolemia.- Hypertension as a Risk Factor.- 84 Review of primary prevention trials of antihypertensive treatment.- 85 Hypertension: why a risk factor for atheroscolerosis?.- 86 Hypertension in the elderly.- Invasive Therapy of Coronary and Cerebrovascular Diseases.- 87 Coronaric and cerebral ischemia: surgery in one or two stages.- 88 Invasive monitoring of coronary blood flow in acute myocardial infarction: pathogenetic and therapeutic relevance.- 89 Prevention of stroke in bilateral carotid lesions.- 90 The role of percuraneous transluminal coronary angioplasty (PTCA) in the treatment of clinical syndromes of coronary atherosclerosis.- 91 Invasive treatment of acute stroke.